Alzheimer’s

Dear Research Advocate: In United for Medical Research’s terrific Amazing Things Podcast series, chairman of the House Labor-HHS Subcommittee, Tom Cole (R-OK) talks about what investments in research mean for the health, well-being and prosperity of America and Americans. Listen in - Chairman Cole can teach us all a thing or two about high impact advocacy! It is important for stakeholders in research to take time to demonstrate the utility of research and innovation investments, speaking out to current and future Congressional champions on both sides of the aisle. With that aim in mind, Research!America has expanded our bipartisan candidate engagement initiative for the midterm elections,...
At The Ohio State University College of Nursing, our faculty are spearheading important research that is making a difference in lives, improving population health and well-being, and decreasing health care costs. Our faculty have over $3 million of funded grants from the National Institutes of Health to conduct cutting-edge research to improve outcomes in vulnerable populations. Research that nurses conduct is focused on solving real-world problems in real time. A substantial number of our research studies, conducted by faculty in our Martha S. Pitzer Center for Women, Children and Youth, focus on optimizing health and well-being of pregnant women and infants, such as a study funded by the...
As the Chief Science Officer of the Alzheimer’s Drug Discovery Foundation (ADDF), I am often asked: what is drug discovery? It is the “innovation engine” that drives breakthroughs in treating diseases. Diseases of the brain, such as Alzheimer’s, are complex. Though the cause of Alzheimer’s isn’t fully understood, scientists continue to uncover new processes that contribute to it. And each new finding into the cause of the disease represents a potential target for drugs to treat it – and an opportunity for innovation. When the ADDF was founded in 1998, the pipeline of drugs in development for Alzheimer’s was limited. The few drugs being developed almost all focused on the same target, beta-...
“Though we’ve been gloried in success, we still have unfinished business” when it comes to tackling cardiovascular disease, said NHLBI Director Dr. Gary Gibbons, highlighting the findings of a new American Heart Association-commissioned analysis at an event in Washington, D.C. last week. The report presented data on what lies ahead in cardiovascular disease prevalence and costs over the next few decades. Projections found more than 131 million people – or about 45 percent of the U.S. population – could suffer from cardiovascular disease by 2035, and annual costs related to this – both direct medical costs and lost productivity – could surpass $1 trillion; that’s more than all other chronic...
Dear Research Advocate, The President’s signature on hard fought funding and tax legislation was enough to end the year on a high note, but there’s more good news: In an interview on C-SPAN , Senate HELP Committee Chairman Lamar Alexander (R-TN) said what many of us have been waiting to hear: “Number one, what we want to turn our attention to [in 2016] is what we call the Innovation Bill.” After the 21st Century Cures pay-fors were used to help offset lost revenues in the FY16 Omnibus/Tax package, the prospects for mandatory NIH and FDA funding seemed weak. However, not only did Chairman Alexander reiterate his support for mandatory funding, but House Energy and Commerce Committee Chairman...

Sidebar Quote

If concerted, long-term investments in research are not made, America will lose an entire generation of young scientists.
Brenda Canine, PhD; McLaughlin Research Institute, Montana